A biologic is produced inside living system, like a microorganism, plant or animal cell, or both. The majority of biologics are huge, complex compounds or molecule mixtures. Recombinant DNA technology is used to make several biologics. Biologics are made from living systems that can be sensitive to even modest modifications in the manufacturing process. Small variations in the manufacturing process can have a big impact on the final biologic's composition and, more crucially, how it works in the body.
Any molecule created by living beings is referred to as a biomolecule. As a result, the vast majority of them are organic molecules. Polysaccharides, amino acids and proteins, nucleic acids (DNA and RNA), and lipids are the four major types of macromolecules found in and produced by living organisms. Over the last two decades, there has been a clear shift away from traditional chemically synthesized small molecule medications and toward large molecule biological drugs or biopharmaceuticals. Despite the fact that many analysts agree on this trend, it is unknown which biomolecules the pharmaceutical industry is currently using for biopharmaceuticals and which biomolecules are in their drug development pipelines that may become the next generation of biopharmaceuticals.
“Antibody-drug cell therapy products when the active ingredient is taken or synthesised from a biological source” are biotherapeutics. Biotherapeutics has become an important aspect of modern medicine, and it is increasingly being utilized to treat and prevent major illnesses, infections, and diseases.
Title : Liver biopsy handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The children's hospital of eastern Ontario grossing protocol
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Haptoglobin-Related Protein Without Signal Peptide as biomarker of renal salt wasting (HPRWSP) in hyponatremia, hyponatremia-related diseases and as new syndrome in alzheimer’s disease
John K Maesaka, NYU Langone Hospital Long Island, United States
Title : Enabling knowledge-driven integration and interoperability in intelligent and ethical transformed health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami, United States
Title : Revolutionizing healthcare and pharma: Artificial intelligence-powered scientific communications and medical writing
Alessandro Gallo, Springer Healthcare, Italy
Title : Understanding drug transport in plasma: the role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up via biodesign-driven biotech and upgraded biomarketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Cell viability assays under radiofrequency application modulated by nanomaterials
Paulo C De Morais, Catholic University of Brasilia, Brazil
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Biosimilars - The current progress
Miroslav Radenkovic, University of Belgrade, Serbia